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Obesity is an ongoing worldwide epidemic. Besides being a medical condition in itself, obesity dramatically increases the risk
of development of metabolic and cardiovascular disease. This risk appears to stem from multiple abnormalities in adipose
tissue function leading to a chronic inflammatory state and to dysregulation of the endocrine and paracrine actions of
adipocyte-derived factors. These, in turn, disrupt vascular homeostasis by causing an imbalance between the NO pathway
and the endothelin 1 system, with impaired insulin-stimulated endothelium-dependent vasodilation. Importantly, emerging
evidence suggests that the vascular dysfunction of obesity is not just limited to the endothelium, but also involves the other
layers of the vessel wall. In particular, obesity-related changes in medial smooth muscle cells seem to disrupt the physiological
facilitatory action of insulin on the responsiveness to vasodilator stimuli, whereas the adventitia and perivascular fat appear
to be a source of pro-inflammatory and vasoactive factors that may contribute to endothelial and smooth muscle cell
dysfunction, and to the pathogenesis of vascular disease. While obesity-induced vascular dysfunction appears to be reversible,
at least in part, with weight control strategies, these have not proved sufficient to prevent the metabolic and cardiovascular
complication of obesity on a large scale. While a number of currently available drugs have shown potentially beneficial
vascular effects in patients with obesity and the metabolic syndrome, elucidation of the pathophysiological mechanisms
underlying vascular damage in obese patients is necessary to identify additional pharmacologic targets to prevent the
cardiovascular complications of obesity, and their human and economic costs.
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Adult obesity, defined as a body mass index (BMI; calculated
as weight in kilograms divided by height in metres squared)
of 30.0 or higher, is a recognized worldwide epidemic (Born-
stein et al., 2008). Until a few years ago, overweight and
obesity were considered a problem limited to high-income
countries. However, they are now dramatically on the rise
also in low- and middle-income nations, particularly in urban
settings.
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One of the most dramatic aspects of the epidemic is that
obesity is not only a medical condition in itself but also a risk
factor for the development of metabolic and cardiovascular
disease (CVD) in adults (Haslam and James, 2005; Mokdad
et al., 2003) and in children (Berenson et al., 1998; Goran and
Gower, 1998; Arslanian, 2002; Caprio, 2002). Obesity, par-
ticularly when presenting with a central distribution, is fre-
quently associated with dyslipidaemia (raised triglycerides
and lowered high-density lipoprotein cholesterol), elevated
BP, and abnormal fasting glucose levels. This cluster is now
well recognized and is referred to as the metabolic syndrome
(Grundy et al., 2004; Alberti et al., 2009). Even if the defini-
tion of the metabolic syndrome does not contain many of the
factors that determine absolute risk, such as age, sex, cigarette
smoking and low-density lipoprotein cholesterol, its presence
is associated with twice the risk of developing CVD over the
next 5–10 years and a fivefold increase in risk for type 2
diabetes mellitus compared with individuals without the
syndrome.
Several pathophysiological mechanisms have been postu-
lated as a link between central adiposity and the metabolic
syndrome. In particular, insulin resistance and hyperinsuli-
naemia have increasingly been recognized to play a pivotal
role in the development of the various components of the
metabolic syndrome phenotype (Kahn and Flier, 2000). Even
if the precise mechanisms underlying the vascular abnormali-
ties and the increased cardiovascular risk associated with
obesity have not been fully elucidated, an impaired vasodi-
lation might affect both peripheral vascular resistance and
the delivery of substrates to metabolically active tissues,
thereby contributing to both hypertension and the metabolic
derangements. A thorough understanding of these mecha-
nisms could have important clinical implications, leading to
the development of therapeutic strategies aimed at reducing
the metabolic and cardiovascular risk.
Therefore, in this article we will review the effects of
obesity on adipose tissue function, including adipocytokine
secretion; we will touch upon the available evidence concern-
ing putative mechanisms whereby obesity and insulin resis-
tance might negatively affect vascular function and increase
cardiovascular risk; and, finally, we will discuss available
therapeutic approaches, including their limitations and
potential side effects.
Obesity, adipose tissue distribution
and adipose tissue function
In the last decade, a wealth of data has shown that adipocytes
possess several roles beyond that of an energy storage depot,
including, but not limited to, endocrine and immune func-
tions. Additionally, we have become increasingly aware that
body fat distribution varies significantly in lean and obese
individuals and may affect the impact of obesity on meta-
bolic and cardiovascular risk. (Bouchard et al., 1993). After
the initial recognition that excess fat stored in the trunk
(android obesity) could exert more deleterious metabolic
effects than fat stored on the limbs (gynoid obesity) (Vague,
1956), several of cross-sectional and prospective studies have
confirmed that upper body fat accumulation is linked to the
presence of metabolic abnormalities (Bjorntorp, 1991) and to
an increased risk of dyslipidaemia (Kissebah et al., 1989),
hypertension (Cassano et al., 1990) and type 2 diabetes (Chan
et al., 1994; Carey et al., 1997). Even if several fat compart-
ments can be identified in the upper body (i.e. subcutaneous,
subfascial and visceral fat, comprising omental, mesenteric
and periorgan adipose tissue), the adipose regions that are
drained by the portal circulation (omental and mesenteric)
appear to exert the most pronounced metabolic effects
(Bjorntorp, 1990). Compared with other types of adipose
cells, portal adipocytes are exquisitely sensitive to stimuli that
mobilize free fatty acids (FFA) due to a high number of
b-adrenergic receptors and a relatively weak a-adrenergic
inhibition (Rebuffe-Scrive et al., 1989; 1990). This sensitivity
leads to high portal FFA concentrations, which, in turn, exert
profound actions on the hepatic regulation of energy
metabolism. In particular, exposure of the liver to elevated
FFA concentrations is followed by an increased synthesis and
secretion of very-low-density lipoprotein (VLDL) (Sniderman
and Cianflone, 1995), stimulation of gluconeogenesis (Fer-
rannini et al., 1983), hepatic insulin resistance (Bevilacqua
et al., 1987) and reduced hepatic clearance of insulin. Further-
more, the consequent hyperinsulinaemia may lead to the
onset of hypertension (Reaven and Hoffman, 1987).
The adipose tissue provides vital information about its
own mass and the whole body’s nutritional status to the
brain and to insulin-sensitive organs and tissues through the
synthesis and secretion of a number of adipokines such as
leptin, adiponectin and resistin (Lee et al., 2009; Galic et al.,
2010). Leptin participates in the physiological regulation of
appetite, by signalling the level of satiety to the brain (Ahima
and Flier, 2000). Paradoxically, the majority of obese indi-
viduals have elevated circulating leptin levels, likely second-
ary to leptin resistance (Martin et al., 2008). Furthermore,
high leptin concentrations correlate with adverse cardiovas-
cular outcomes in obese patients (Sweeney, 2010). Adiponec-
tin is an adipocyte-derived peptide that circulates in high
concentrations in plasma (Chiarugi and Fiaschi, 2010) and
whose actions include enhancement of insulin-mediated
glucose uptake in skeletal muscle, suppression of hepatic
glucose production and amelioration of insulin resistance
(Yamauchi et al., 2002). Adiponectin’s concentrations, unlike
most of the other adipokines, are inversely correlated with
BMI (Matsubara et al., 2002) and visceral fat (Lara-Castro
et al., 2006), and are reduced in patients with obesity and
type 2 diabetes (Weyer et al., 2001). Resistin, an adipocyte-
specific peptide in rodents, in humans is mainly produced by
macrophages. It has been suggested that resistin may play a
role in the development of insulin resistance and obesity
(Lazar, 2007) and that its levels may be increased in patients
with type 1 and 2 diabetes (Fehmann and Heyn, 2002).
The increase of adipose tissue mass in obesity is accom-
panied by macrophage infiltration, secondary to the produc-
tion of monocyte chemoattractant protein-1 (MCP-1) and
other pro-inflammatory cytokines, such as TNF-a and IL-6, by
preadipocytes and endothelial cells (Wellen and Hotamisligil,
2003). It is now clear that inflammation may play an impor-
tant role in causing both insulin resistance and vascular dys-
function. This concept was originally postulated by the
pioneering work of Hotamisligil et al. (1996), who demon-
strated that TNF-a is expressed in adipose tissue and that its
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expression is induced by obesity, hence contributing to sys-
temic insulin resistance. Subsequent studies have largely sup-
ported this hypothesis and have also demonstrated that the
vasculature is an important target of TNF-a, as discussed later.
Obesity and endothelial dysfunction
The presence of endothelial dysfunction, characterized by
decreased availability of NO, in patients with obesity and
insulin resistance was first reported by Steinberg and cowork-
ers over a decade ago. These authors demonstrated a blunted
increase of leg blood flow in response to graded intra-arterial
doses of the muscarinic receptor agonist methacholine in
patients with elevated BMI or type 2 diabetes compared with
lean controls (Steinberg et al., 1996). Their findings were sub-
sequently replicated by other investigators (Perticone et al.,
2001; Van Guilder et al., 2006) and by our group in a study
showing that patients with the metabolic syndrome second-
ary to central obesity have impaired forearm vasodilator
response to ACh (Tesauro et al., 2005). More recently, Bigor-
nia et al. (2010) have demonstrated that also flow-mediated
dilation (FMD; an ultrasound-based non-invasive endothelial
function test) of the brachial artery is impaired in severely
obese patients and that weight loss leads to an improvement
of endothelial function and metabolic parameters in these
individuals. Of interest, the improvement correlates most
strongly with glucose levels and is independent of weight
changes, suggesting that the relationship between obesity
and brachial artery endothelial dysfunction is not direct and
is likely mediated by obesity-induced metabolic abnormali-
ties (Bigornia et al., 2010). In keeping with these findings,
Woo et al. (2004b) have reported that mild to moderate
obesity is associated with impaired endothelium-dependent
dilation of the brachial artery in otherwise healthy young
children. Of note, the vascular abnormalities in this group
appear to be partially reversible by even a short programme of
dietary modification, particularly when in combination with
exercise (Woo et al., 2004a). Taken together, the findings of
these studies suggest that interventions aimed at reducing
weight may lead to a reversal of endothelial dysfunction in
obese individuals, thus potentially reducing risk of develop-
ing diabetes and CVD.
Besides the biological deficit of NO, endothelial dysfunc-
tion is characterized by an enhanced bioactivity of vasocon-
strictor and proatherogenic factors. In particular, endothelin
1 (ET-1), the most potent vasoconstrictor peptide synthesized
by the endothelial cells, appears to play a central role in the
pathophysiology of the vasomotor abnormalities associated
with endothelial dysfunction and in the formation and pro-
gression of the atherosclerotic plaque (Levin, 1995). It is
therefore conceivable that an increased activity of the ET-1
system may contribute to the abnormal vascular homeostasis
of obese patients. The first evidence in support to this
hypothesis was reported by Mather et al. (2004), who inves-
tigated the interactions of the ET-1 and NO system in obese or
type 2 diabetic individuals. These authors observed that
antagonism of ET-1 constrictor tone by use of BQ-123, a
selective blocker of the endothelin receptor type A (ETA),
corrected the defect in endothelium-dependent vasodilation
seen in these patients, thus suggesting an important contri-
bution of ET-1 to their endothelial dysfunction (Mather et al.,
2004). In keeping with these findings, we have demonstrated
an increased ET-1-dependent vasoconstrictor activity in the
forearm circulation of overweight and obese individuals, but
not in lean controls, with a linear relationship between the
degree of vasodilation induced by ET-1 receptor blockade
with BQ-123 and BMI (Cardillo et al., 2004). Furthermore, we
have observed that patients with central adiposity and the
metabolic syndrome, in addition to enhanced intravascular
ET-1 activity, also have impaired vasoconstrictor response
to the inhibition of NO synthesis by NG-monomethyl-L-
arginine (L-NMMA), indicating a concomitant decrease of
NO-dependent vasodilator capacity (Tesauro et al., 2005).
Taken together, these findings clearly suggest an imbalance
between the NO pathway and the ET-1 system in the vessels
of obese patients, with a shift of the normal prevalence of
NO-mediated vasodilator tone towards an enhanced ET-1-
mediated vasoconstriction.
Obesity, insulin and endothelium-
dependent vasodilation
Several potential mechanisms may explain the development
of endothelial dysfunction and of vascular abnormalities in
obese patients. Given the impact of obesity on glucose
metabolism and the effects of insulin on the vasculature,
research has focused on the effects of insulin resistance on
vascular homeostasis. Physiologically, insulin stimulates
glucose uptake in insulin-sensitive tissues, such as the skeletal
muscle and adipose tissue, by causing the translocation of the
insulin-responsive glucose transporter (GLUT-4) to the cell
surface, which, in turn, allows glucose entrance into the cell.
This effect is the final result of the binding of insulin to its
receptor on the cell membrane followed by activation of
intracellular pathways that involves the insulin receptor sub-
strate (IRS)-1, phosphoinositide 3 kinase (PI3K) and PKB (also
known as Akt) (Saltiel and Kahn, 2001). It is now known that
insulin receptors are present on endothelial cells, where they
activate both the PI3K/Akt pathway and the rat sarcoma/
MAPK (RAS/MAPK) cascade leading to NO and ET-1 synthesis
respectively (Zeng et al., 2000; Muniyappa et al., 2008). In
physiological conditions, the net effect of insulin stimulation
on the endothelial cells results in NO-mediated vasodilation,
which may contribute to the delivery of insulin and glucose
to metabolically active tissues, thereby increasing insulin
sensitivity (Baron and Clark, 1997). In contrast, in states
associated with endothelial dysfunction, such as obesity,
insulin-mediated vasodilation is impaired and may contrib-
ute to the pathophysiology of insulin resistance and of the
metabolic syndrome (Laakso et al., 1990; Kim et al., 2006).
The first evidence of a possible haemodynamic effect of
insulin was reported by Baron et al. (1995)., who demon-
strated that in healthy individuals, the infusion of the
hormone-induced NO-dependent vasodilation of resistance
vessels in the leg circulation, which resulted in increased
skeletal muscle blood flow and concurrent enhancement of
insulin-stimulated glucose uptake (Baron et al., 1995). Even
though these findings have been replicated by some investi-
gators (Tack et al., 1996; de Haan et al., 1997), others, includ-
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ing our group, have failed to observe a direct vasodilator
effect of the hormone (Cardillo et al., 1998). The reasons for
these diverging findings are not entirely clear; however, the
dose of insulin employed and the duration of the infusion
may be important factors (Yki-Jarvinen and Utriainen, 1998).
In particular, the majority of the studies that reported an
increase in limb blood flow following insulin administration
achieved supraphysiological concentrations of the hormone
(Tack et al., 1996) or observed the effect only after several
hours of infusion (Zhang et al., 2004). Therefore, the role of
insulin-mediated vasodilation in the stimulation of glucose
uptake in physiological conditions remains uncertain.
A more widely accepted physiological role of insulin is its
ability to increase the available capillary surface area in the
skeletal muscle circulation, thus augmenting the delivery of
insulin itself, glucose and other nutrients to the myocytes
(Clark et al., 2003). This notion supports a functional cou-
pling between the microvascular effects of insulin, muscle
perfusion and glucose utilization. Accordingly, a decrease in
muscle perfusion may blunt the delivery of insulin and
glucose, and lead to impaired glucose tolerance, whereas a
reduced exposure of circulating triglyceride-containing lipo-
proteins to endothelial lipoprotein lipase may contribute to
dyslipidaemia (Lind and Lithell, 1993), suggesting that
microvascular dysfunction may precede and contribute to
the development of insulin resistance and the metabolic
syndrome.
Obesity, insulin and the
endothelin system
In addition to stimulating NO production, insulin promotes
the synthesis and release of ET-1 by endothelial cells. This in
vivo effect was originally demonstrated by our group in the
forearm circulation of healthy volunteers by using BQ-123 as
pharmacological tools. In this experimental setting, the com-
bined infusion of BQ-123 and BQ-788 or the administration
of insulin alone in the brachial artery did not affect resting
forearm blood flow values. However, the blockade of ET-1
receptors during insulin infusion was associated with a sig-
nificant vasodilator response, consistent with the presence of
an increased ET-1-dependent vasoconstrictor tone. Further-
more, during ET-1 receptor blockade, the vasoconstrictor
response to NO synthesis inhibition with L-NMMA was sig-
nificantly higher after insulin infusion than in the absence of
hyperinsulinaemia, indicating an increment in NO bioavail-
ability (Cardillo et al., 1999). Based on these findings, we
postulated that, in the skeletal muscle circulation under
physiological conditions, insulin stimulates the release of
both NO and ET-1 from the endothelium, albeit with a neutral
haemodynamic response to the hormone due to an equilib-
rium between these opposing vasoactive stimuli. This hypoth-
esis is supported by the experimental work of Vicent et al.
(2003) who reported reduced endothelial NO synthase (eNOS)
and ET-1 mRNA levels in endothelial cells from a vascular
endothelial cell insulin receptor knockout (VENIRKO) mouse
model.
A pivotal biochemical abnormality observed in insulin-
resistant individuals with obesity or type 2 diabetes is the
specific impairment of the PI3K-dependent signalling
cascade, while the MAPK pathway is spared (Cusi et al., 2000).
The potential pathophysiological implications of this abnor-
mality are relevant, since insulin resistance is usually accom-
panied by a compensatory hyperinsulinaemic state to
maintain euglycaemia. Hyperinsulinaemia may overstimu-
late the normally functioning MAPK-dependent pathways,
an effect that cannot be balanced by the abnormal PI3K
cascade. At the vascular level, this would lead to an increased
endothelial production of ET-1 and to a reduced synthesis of
NO, with consequent endothelial dysfunction and increased
vascular tone (Figure 1) (Kim et al., 2006). This hypothesis is
supported by the findings from Mather et al. (2002), who
demonstrated that insulin-resistant patients with obesity or
type 2 diabetes have enhanced ET-1-mediated vascular tone
and blunted response to the infusion of methacholine,
and that ET-1 importantly contributes to the abnormal
endothelium-dependent vasodilation present in these
patients.
Additional mechanisms of impaired
vascular reactivity in obesity
Adipokines
In animal experiments, hyperleptinaemia significantly
impairs coronary endothelial function in vivo and in vitro, as
assessed by response to intracoronary infusion of Ach
(Yamauchi et al., 2002). Since human endothelial cells also
express leptin receptors (Yamauchi et al., 2002) and hyperlep-
tinaemia is an independent risk factor for coronary artery
disease and a strong predictor of acute myocardial infarction
(Soderberg et al., 1999; Ren, 2004), it is reasonable to specu-
late that high circulating leptin levels such as those observed
in obese patients may induce endothelial dysfunction in the
human vasculature. These effects may be mediated by uncou-
pling of eNOS with depletion of endothelial NO and
increased production of peroxynitrite (ONOO-), as suggested
by experiments in obese mice (Korda et al., 2008). Ghrelin is
a gastric peptide that plays a relevant role in the central
regulation of food intake (Kojima et al., 1999; van der Lely
et al., 2004). Recent evidence has indicated that ghrelin exerts
favourable cardiovascular effects (Tesauro et al., 2010) and
that its levels are decreased in obese patients (Tschop et al.,
2001). In particular, studies conducted by our group have
shown that, in patients with obesity-related metabolic syn-
drome, ghrelin improves endothelial function (Tesauro et al.,
2005) by restoring the NO/ET-1 balance (Tesauro et al., 2009).
Furthermore we have demonstrated that ghrelin acutely
stimulates production of NO in endothelial cells through a
signalling pathway that involves PI3K, Akt and eNOS (Ian-
torno et al., 2007).
In vitro studies have also shown that adiponectin may
exert beneficial vascular effects by stimulating NO production
by endothelial cells via PI3K-dependent pathways (Chen
et al., 2003). Furthermore, adiponectin may decrease TNF-a-
induced production of asymmetric dimethylarginine (ADMA)
(Eid et al., 2007) and improve the redox state of the endot-
helium by suppressing reduced nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase-derived superoxide
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Figure 1
Interactions among endothelial, smooth muscle and adventitial cells in the physiological regulation of vasoactive function. In conditions of insulin
resistance, the physiological balance between vasoconstrictor and vasodilator pathways in endothelial cells is shifted towards a predominant
vasoconstriction, due to the prevalent activation of the endothelin system. In addition, the impairment of adipocyte function and production of
inflammatory cytokines within the perivascular adipose tissue leads to increase ROS production and oxidative stress which, in turn, increases
smooth muscle cell contractility.
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generation (Motoshima et al., 2004). Therefore, the low levels
of adiponectin observed in obese individuals (Weyer et al.,
2001) may lead to abnormal endothelial function.
Oxidative stress
Endothelial dysfunction in obesity is a multifactorial condi-
tion in which reactive oxygen species (ROS) play a key patho-
genetic role. (Siekmeier et al., 2008; Otani, 2010) In
particular, ROS generated in the vascular wall have been
shown to represent a major determinant of NO synthesis and
bioactivity (Siekmeier et al., 2008). A number of intracellular
enzymatic activities such as xanthine oxidase (XO), nicotina-
mide adenine dinucleotide (NADH)/NADPH oxidase, peroxi-
dases, cytochromes P450 system, the mitochondrial
respiratory chain, lipoxygenase and COX may generate ROS.
However, XO, NADH/NADPH oxidase, and uncoupling of
eNOS represent the main sources of these highly toxic com-
pounds in the vasculature (Cai and Harrison, 2000). Endot-
helial cell generation of ROS is triggered by high circulating
levels of pro-inflammatory cytokines generated in the visceral
adipose tissue through the action of the local renin–
angiotensin system (Dandona et al., 2007) and by low adi-
ponectin levels. The excessive oxidative stress decreases NO
bioavailability through multiple mechanisms including gen-
eration of ONOO- anions from a reaction of NO with super-
oxide; reduction in NO synthesis secondary to uncoupling of
eNOS through ROS-induced oxidation and depletion of the
eNOS cofactor, tetrahydrobiopterin (BH4) (Bendall et al.,
2005); enhanced consumption by high levels of superoxide;
inhibition of the enzyme dimethylarginine dimethylamino-
hydrolase (DDAH), with consequent increase in circulating
levels of ADMA, a competitive inhibitor of NO synthesis. (Jia
et al., 2006)
FFAs
An additional metabolic feature of obesity is the presence of
elevated circulating levels of FFA. A role of these lipids in the
pathogenesis of endothelial dysfunction has been suggested
by the evidence that the infusion of a solution of FFA in
healthy humans impairs endothelium-dependent vasodila-
tion (Steinberg et al., 1997; Watanabe et al., 2005), and phar-
macological lowering of FFA with acipimox, a nicotinic acid
analogue, leads to an improvement of microvascular function
in obese women (de Jongh et al., 2004). Several mechanisms
may account for the detrimental effects of circulating FFA on
vascular function, including, but not limited to, enhanced
oxidative stress due to activation of the renin–angiotensin
system (Watanabe et al., 2005) and ET-1 release (Piatti et al.,
1996).
TNF-a
Another potential contributor to the metabolic and vascular
abnormalities observed in obesity is TNF-a. The circulating
levels of this inflammatory cytokine are elevated in obese
individuals and are associated with endothelial activation
and a blunted response to the infusion of the NO precursor
L-arginine (Ziccardi et al., 2002). In keeping with these obser-
vations, Rask-Madsen et al. (2003) and colleagues have shown
that infusion of TNF-a in healthy humans inhibits the stimu-
latory effects of insulin on glucose uptake and reduces
endothelium-dependent vasodilation. A number of studies
have investigated the potential mechanisms underlying the
detrimental effects of TNF-a on insulin metabolism and vas-
cular function. Incubation of human vascular endothelial
cells with TNF-a produces a marked down-regulation of eNOS
expression (Yoshizumi et al., 1993; Mohamed et al., 1995)
and induces the synthesis of ET-1 and plasminogen activator
inhibitor 1 (Mohamed et al., 1995). Furthermore, TNF-a may
activate NADH oxidase in vascular smooth muscle cells, thus
increasing ROS generation and reducing NO bioavailability
(De Keulenaer et al., 1998). In addition to these direct effects,
TNF-a may also induce vascular dysfunction indirectly by
stimulating lipolysis and FFA release (Pittas et al., 2004). In
our laboratory, we investigated the role of TNF-a in the vas-
cular dysfunction associated with the metabolic syndrome
by using the TNF-a neutralizing antibody infliximab. We
observed that TNF-a blockade enhances the stimulatory
effects of insulin not only on endothelium-dependent, but
also on endothelium-independent vasodilator reactivity. The
effect of infliximab on vascular function was not additive to
that observed following the administration of the antioxi-
dant vitamin C, suggesting that TNF-a-related vasculopathy
in these patients is likely related to increased oxidative stress
(Tesauro et al., 2008). To further characterize the mechanism
of abnormal insulin-stimulated vascular reactivity in patients
with central obesity, we compared the effects of insulin on
vascular responses to vasodilators acting through different
mechanisms in healthy individuals and in patients with
metabolic syndrome (Schinzari et al., 2010). In the former
group, hyperinsulinaemia not only enhanced NO-dependent
vasodilation in response to ACh infusion, but also increased
the effects of the endothelium-independent vasodila-
tors sodium nitroprusside, an exogenous NO donor, and
verapamil, a calcium channel blocker that exerts
NO-independent vasodilator actions. In contrast, no
enhancement of vasodilator reactivity to any of these agents
was observed during hyperinsulinaemia in patients with the
metabolic syndrome. Taken together, these findings indicate
that the abnormalities of insulin signalling in resistance
vessels of patients with central obesity are not limited to the
vascular endothelium but involve smooth muscle cell func-
tion, suggesting a novel mechanism of insulin action on
blood vessels and a potential additional link between obesity,
insulin resistance and vascular dysfunction.
Obesity, vascular dysfunction and the
perivascular adipose tissue (PVAT)
In addition to the presence of systemic factors linking obesity
to impaired vasodilator function, a vasoregulatory role for
local deposits of fat around arterial vessels has recently been
postulated (Yudkin et al., 2005). Following the initial evi-
dence that PVAT significantly influences vascular responsive-
ness in rat aortas in vitro (Soltis and Cassis, 1991), Gao et al.
(2007) demonstrated that PVAT exerts anticontractile effects
by releasing a diffusible mediator that triggers endothelial
NO release and subsequent calcium-dependent potassium
channel activation, as well as through an endothelium-
independent mechanism involving hydrogen peroxide
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(H2O2) and activation of soluble guanylyl cyclase. In humans,
the vasoactive effects of PVAT were initially reported in
medium-sized arteries (Gao et al., 2005) and have more
recently been confirmed in small arteries (Greenstein et al.,
2009). In particular, Greenstein et al. (2009) conducted
elegant experiments on human arteries 250–350 mm in diam-
eter, with and without PVAT, taken from s.c. gluteal fat biop-
sies from healthy individuals and from obese patients with
the metabolic syndrome. These authors demonstrated that,
in physiological conditions, PVAT around small arteries
secretes one or more factors that promote vasodilation by
increasing NO bioavailability. Among them, adiponectin
appeared to be the main candidate, since the anticontractile
responses were completely abolished when arteries with PVAT
from healthy individuals were incubated with an adiponectin
type 1 receptor-blocking fragment (Greenstein et al., 2009).
The dilator effect of PVAT was lost in the obese patients with
metabolic syndrome, and was accompanied by an increase in
adipocyte area and by immunohistochemical evidence of
higher expression of TNF-a receptor 1, a marker of inflam-
mation. Of note, the ‘obese’ phenotype could be reproduced
by adding TNF-a or IL-6 to the PVAT around healthy blood
vessels, which, in turn, could be blocked by free radical scav-
engers or cytokine antagonists. Finally, low oxygen or
hypoxia stimulated an inflammatory phenotype in PVAT
with loss of the anticontractile properties (Greenstein et al.,
2009). Since the partial pressure of oxygen is reduced in the
adipose tissue of overweight/obese subjects and is associated
with lower capillary density and tissue inflammation
(Pasarica et al., 2009), these findings further support a promi-
nent role for PVAT-derived ROS and inflammatory cytokines
in adversely modulating vascular function. A possible role of
epicardial adipose tissue, which directly surrounds the coro-
nary arteries, in the development of coronary atherosclerosis
has also been proposed, and a significant relationship
between epicardial fat volume and the presence of coronary
atherosclerosis measured by multislice computed tomogra-
phy has been reported (Djaberi et al., 2008; Wang et al.,
2009a). Taken together, the findings of these investigations
suggest that PVAT may play an important role in the main-
tenance of normal vascular function and that in obesity and
other insulin-resistant states, an abnormal PVAT function
may contribute to the pathogenesis of atherosclerosis.
Therapeutic targets of endothelial
dysfunction in obesity
Since endothelial dysfunction represents a dynamic response
of the endothelium that is potentially reversible, a number of
clinical trials have investigated the effect of weight loss on
various markers of endothelial function. Despite significant
differences in the therapeutic approach employed (diet,
surgery, medications and exercise, alone or in various combi-
nations) the majority of these investigations have reported
similar beneficial effects on vascular function (e.g. improved
NO bioavailability, amelioration of lipid and glucose metabo-
lism, modulation of adipokine release, reduced inflammation
and decreased oxidative stress) with these interventions
(Table 1).
Exercise and diet
Several studies have examined the effects of diet and/or exer-
cise on obesity-induced endothelial dysfunction both in chil-
dren (Woo et al., 2004a) and in adults (Ziccardi et al., 2002;
Pierce et al., 2008; Bigornia et al., 2010; Mavri et al., 2011),
showing consistent improvement in endothelium-dependent
dilation. While weight loss through diet and/or exercise would
be the most appropriate therapy to reverse the vascular abnor-
malities present in obese individuals, the long-term efficacy of
these interventions is limited (Ayyad and Andersen, 2000).
Therefore, several classes of drugs have been tested in patients
with obesity with or without the metabolic syndrome. Among
the currently approved antiobesity agents, orlistat, a saturated
derivative of the natural inhibitor of pancreatic lipases lipsta-
tin, improved FMD in 42 young obese women treated for
12 weeks (Sekuri et al., 2003). However, these findings were
not reproduced in another group of patients with uncompli-
cated obesity receiving orlistat in addition to a calorie-
restricted diet (Brook et al., 2004), leaving uncertainty
regarding the effects of this medication on vascular function.
The most common side effects of orlistat include headache,
abdominal pain/discomfort, fecal urgency and fatty/oily stool.
Oral hypoglycemics
Metformin, the most widely prescribed oral agent for the
treatment of diabetes, is a biguanide that suppresses endog-
Table 1
Effects of weight reduction beneficial to vascular function
Endothelial
function
Adhesion
molecules
Glucose
metabolism
Lipid
metabolism Adipokines
Oxidative
stress Inflammation Coagulantion
↑ FMDa,b,c
↑ ACh Responseb
↓ ICAM-1d
↓ P-Selectind
↓ E-Selectind
↓ FBGa
↓ Insulinc
↓ Cholesterola
↓ LDLa
↓ Triglycerides a,c
↓ Leptinb,c ↓ LDLoxb ↓ CRPa,b,c
↓ TNF-R1c
↓ vWFc
↓ PAIc
aBigornia et al., 2010.
bPierce et al., 2008.
cMavri et al., 2011.
dFerri et al., 1999.
CRP, C-reactive protein; FBG, fasting blood glucose; FMD, flow-mediated dilation; ICAM, intercellular adhesion molecule; LDL, low-density
lipoprotein; LDLox, oxidized LDL; PAI, plasminogen activator inhibitor; TNF-R1, TNF receptor type 1; Vwf, von Willebrand factor.
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enous glucose production, thus leading to decreased insulin
levels (Hundal and Inzucchi, 2003). This agent may exert
beneficial effects on cardiovascular risk factors and is associ-
ated with improved macrovascular outcomes in overweight
patients with type 2 diabetes (UKPDS Group, 1998).
The vascular effects of metformin have not been com-
pletely clarified; however, they appear to be mediated by the
activation of AMP-activated PK (AMPK), a highly conserved,
multisubstrate serine/threonine PK involved in the regula-
tion of cellular and organ metabolism. In vascular endothe-
lial cells, activated AMPK increases phosphorylation of eNOS
at Ser1179 and promotes eNOS association with heat shock
protein 90 (Hsp90), resulting in increased NO synthesis and
bioavailability (Davis et al., 2006). To test the hypothesis that
this drug may improve endothelial function in vivo, Vitale
et al. (2005) randomized 65 obese patients with metabolic
syndrome to treatment with either metformin 500 mg twice
daily or placebo for 3 months. The authors report that FMD
of the brachial artery was significantly improved in the active
treatment group, whereas it remained unchanged in patients
who received placebo (Vitale et al., 2005). In line with these
results, de Aguiar et al. (2006) showed that metformin also
improves microvascular endothelium-dependent vasodila-
tion, measured as the response to intra-arterial infusion of
ACh, in obese first-degree relatives of type 2 diabetic patients
with metabolic syndrome and normal glucose tolerance.
Thus, these results strongly suggest that metformin exerts
beneficial vascular effects also in non-diabetic obese patients
with metabolic syndrome. However, the frequent occurrence
of gastrointestinal side effects, such as diarrhoea and nausea/
vomiting reduces the tolerability of this treatment. Another
class of oral hypoglycaemic drugs, the insulin sensitizers thia-
zolidinediones (TZD) (Yki-Jarvinen, 2004), have shown to
possess important beneficial vascular effects. Their main
mechanism of action is mediated by binding to the peroxi-
some proliferator-activated receptor-g (PPARg), which affects
transcription of several genes involved in glucose and
lipid metabolism (Schoonjans and Auwerx, 2000). However,
recent evidence suggests that TZD may exert acute, gene
transcription-independent effects via AMPK-dependent phos-
phorylation of eNOS at Ser1177 (Morrow et al., 2003) leading to
NO-dependent vasodilation of conduit (Wang et al., 2009b),
as well as resistance vessels (Bradley et al., 2010). Consistent
with the experimental evidence, rosiglitazone has been
shown to exert beneficial effects on endothelial function in
patients with type 2 diabetes independent of glucose lower-
ing (Pistrosch et al., 2004). Our group expanded this observa-
tion by showing that 8 week treatment with pioglitazone
improves the vasodilator response to infusion of bradykinin
in obese hypertensive and hypercholesterolaemic patients
(Campia et al., 2006), suggesting that the improved vascular
function secondary to PPARg stimulation is independent of
body fat mass. Thiazolidinediones are overall well tolerated;
however, they may cause oedema and may precipitate hospi-
talization in patients with heart failure. Furthermore, con-
cerns about an increased cardiovascular risk of rosiglitazone
have been raised. In particular, even if an open-label, non-
inferiority trial was inconclusive about any possible effect of
rosiglitazone on myocardial infarction [hazard ratio 1.14;
95% confidence interval (CI) 0.80–1.63 for myocardial infarc-
tion] (Home et al., 2009), the results of recent meta-analyses
indicate that rosiglitazone use is associated with an increased
risk for myocardial infarction (odds ratio 1.28; 95% CI, 1.01–
1.62; P = 0.04), although not for cardiovascular mortality
(odds ratio 0.99; 95% CI, 0.75–1.32; P = 0.96). (Nissen and
Wolski, 2007; 2010)
Angiotensin receptor antagonists
and antioxidants
Since endothelial dysfunction in patients with the metabolic
syndrome may be due to increased angiotensin (AT)-II activ-
ity and enhanced oxidative stress, Sola et al. (2005) investi-
gated whether irbesartan, an AT-II receptor blocker, and lipoic
acid, an antioxidant, affect endothelial function and inflam-
mation in patients with metabolic syndrome. These investi-
gators reported that short-term treatment with irbesartan,
lipoic acid or both increased FMD compared with placebo,
suggesting that these agents may be potentially beneficial in
improving cardiovascular function in this population.
Resveratrol
Resveratrol is a natural phenolic phytochemical found in the
skin of red grapes, red wine, apples, peanuts, blueberries and
cranberries (Baur and Sinclair, 2006). The potential beneficial
cardiovascular effects of resveratrol have stemmed from epi-
demiological studies indicating that red wine consumption is
inversely related to mortality due to CVDs (Gronbaek, 2002).
Its biological effects are mediated, at least in part, through the
activation of sirtuin-1 (SIRT1), a NAD-dependent class III
histone deacetylase of the sirtuin family (Brooks and Gu,
2009). Several lines of research indicate that SIRT1 plays a
pivotal role in endothelial homeostasis by increasing eNOS
gene expression while reducing baseline and H2O2-stimulated
expression of ET-1 gene (Mattagajasingh et al., 2007), as well
as by regulating pot-translational eNOS acetylation, leading
to increased NO synthesis (Mattagajasingh et al., 2007). Con-
sistent with this experimental evidence and similar to the
effects seen with calories restriction, oral resveratrol supple-
mentation improved FMD in overweight/obese individuals
with mildly elevated BP (Wong et al., 2011).
Conclusions
Obesity is an ongoing worldwide epidemic that affects both
adults and children. Besides being a medical condition in
itself, obesity dramatically increases the risk of development
of metabolic and CVD. This risk appears to stem from mul-
tiple abnormalities in adipose tissue function, leading to a
chronic inflammatory state and to dysregulation of the endo-
crine and paracrine actions of adipocyte-derived factors.
These, in turn, disrupt vascular homeostasis by causing an
imbalance between the NO pathway and the ET-1 system,
with impaired insulin-stimulated endothelium-dependent
vasodilation. Importantly, emerging evidence suggests that
the vascular dysfunction of obesity is not just limited to the
endothelium, but also involves the other layers of the vessel
wall (Figure 1). In particular, obesity-related changes in
medial smooth muscle cells seem to disrupt the physiological
facilitatory action of insulin on the responsiveness to vasodi-
lator stimuli, whereas the adventitia and the perivascular fat
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appear to be a source of pro-inflammatory and vasoactive
factors that may contribute to endothelial and smooth
muscle cell dysfunction and to the pathogenesis of vascular
disease. While obesity-induced vascular dysfunction appears
to be reversible, at least in part, with weight control strategies,
these have not proved sufficient to prevent the metabolic and
cardiovascular complication of obesity on a large scale. While
a number of currently available drugs have shown potentially
beneficial vascular effects in patients with obesity and the
metabolic syndrome, elucidation of the pathophysiological
mechanisms underlying vascular damage in obese patients is
all the more necessary to identify additional pharmacologic
targets to prevent the cardiovascular complications of obesity
and their human and economic costs.
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